Skip to content

Study · Randomized controlled trial · n = 10 · 2013

7 results

Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.

Rotondo A, Janssen P, Mulè F, Tack J

International journal of obesity (2005)31 Jul 2012Cited by 21 (Europe PMC)

PMID22846777 (opens in a new tab)DOI10.1038/ijo.2012.101 (opens in a new tab)PepBankPUB-22846777
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy volunteers, intragastric pressure decreased during nutrient-drink infusion after placebo (4.1 mm Hg) and after 0.3, 0.6 and 1.2 mg liraglutide (3.0, 2.1 and 2.6 mm Hg).

    In plain wordsIn healthy volunteers, pressure inside the stomach fell during a nutrient drink with placebo and with each liraglutide dose.

    Peptide
    Liraglutide
    Outcome
    MixedIntragastric pressure decrease during nutrient-drink infusion
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    0.3, 0.6 and 1.2 mgAs given in this study (human).

    Measurements

    IGP decrease
    4.1 mm Hg
    placebo
    IGP decrease
    3 mm Hg
    liraglutide 0.3 mg
    IGP decrease
    2.1 mm Hg
    liraglutide 0.6 mg
    IGP decrease
    2.6 mm Hg
    liraglutide 1.2 mg

    Source sentences

    Summary
    During nutrient-drink infusion, IGP decreased with 4.1±0.7, 3.0±0.4, 2.1±0.3 and 2.6±0.4 mm Hg (placebo, 0.3, 0.6 and 1.2 mg liraglutide, respectively; P<0.05).
    1 context sentence
    Summary · context
    Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, 1.2 mg liraglutide lowered the maximum-tolerated nutrient-drink volume compared with placebo.

    In plain wordsIn healthy volunteers, 1.2 mg liraglutide lowered the largest drink volume they could tolerate, compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMaximum-tolerated volume of nutrient drink, 1.2 mg
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Gastrointestinal
    Studied dose
    1.2 mgAs given in this study (human).

    Measurements

    Maximum-tolerated volume
    695 ml
    liraglutide 1.2 mg
    Maximum-tolerated volume
    1008 ml
    placebo

    Source sentences

    Summary
    The maximum-tolerated volume was not different, except after treatment with 1.2 mg liraglutide (695±135 ml) compared with placebo (1008±197 ml; P<0.05)
    1 context sentence
    Summary · context
    Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers, the maximum-tolerated nutrient-drink volume after 0.3 and 0.6 mg liraglutide did not differ from placebo.

    In plain wordsIn healthy volunteers, 0.3 and 0.6 mg liraglutide did not change the largest drink volume they could tolerate, compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeMaximum-tolerated volume of nutrient drink, 0.3 and 0.6 mg
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Gastrointestinal
    Studied dose
    0.3 and 0.6 mgAs given in this study (human).

    Source sentences

    Summary
    The maximum-tolerated volume was not different, except
    1 context sentence
    Summary · context
    Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration.
  4. 04HumanRandomized controlled trialSafety outcome

    In healthy volunteers, 1.2 mg liraglutide induced nausea in all volunteers.

    In plain wordsIn healthy volunteers, 1.2 mg liraglutide caused nausea in all of them.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedNausea at 1.2 mg
    Study

    n = 10

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.2 mgAs given in this study (human).

    Source sentences

    Summary
    however, 1.2 mg liraglutide induced nausea in all volunteers.
    1 context sentence
    Summary · context
    Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration.
  5. 05HumanRandomized controlled trialMechanism

    In healthy volunteers, 0.6 mg liraglutide significantly decreased gastric accommodation to the meal compared with placebo.

    In plain wordsIn healthy volunteers, 0.6 mg liraglutide reduced how much the stomach relaxed to take in a meal, compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseGastric accommodation to the meal, 0.6 mg
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    0.6 mgAs given in this study (human).

    Measurements

    Gastric accommodation
    168 ml
    placebo
    Gastric accommodation
    78.8 ml
    liraglutide 0.6 mg

    Source sentences

    Summary
    significantly decreased gastric accommodation to the meal (168±27 vs 78.8±36.4 ml after treatment with placebo and 0.6 mg liraglutide, respectively; P<0.05).
    1 context sentence
    Summary · context
    Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration.
  6. 06HumanRandomized controlled trialMechanism

    In healthy volunteers, liraglutide did not affect perception of gastric distension in the barostat study.

    In plain wordsIn healthy volunteers, liraglutide did not change how they felt stomach stretching.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastric perception in barostat study
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    liraglutide did not affect the perception or compliance
    1 context sentence
    Summary · context
    Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration.
  7. 07HumanRandomized controlled trialMechanism

    In healthy volunteers, liraglutide did not affect gastric compliance in the barostat study.

    In plain wordsIn healthy volunteers, liraglutide did not change how easily the stomach stretched.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastric compliance in barostat study
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    liraglutide did not affect the perception or compliance
    1 context sentence
    Summary · context
    Ten healthy volunteers (HVs) were tested after placebo, 0.3, 0.6 or 1.2 mg liraglutide administration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.